Literature DB >> 33444221

Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

Martin Reincke1, Adriana Albani1, Guillaume Assie2, Irina Bancos3, Thierry Brue4, Michael Buchfelder5, Olivier Chabre6, Filippo Ceccato7, Andrea Daniele7, Mario Detomas8, Guido Di Dalmazi9, Atanaska Elenkova10, James Findling11, Ashley B Grossman12, Celso E Gomez-Sanchez13, Anthony P Heaney14, Juergen Honegger15, Niki Karavitaki16,17,18, Andre Lacroix19, Edward R Laws20, Marco Losa21, Masanori Murakami1,22, John Newell-Price23, Francesca Pecori Giraldi24, Luis G Pérez-Rivas1, Rosario Pivonello25, William E Rainey26, Silviu Sbiera8, Jochen Schopohl1, Constantine A Stratakis27, Marily Theodoropoulou1, Elisabeth F C van Rossum28, Elena Valassi29, Sabina Zacharieva10, German Rubinstein1, Katrin Ritzel1.   

Abstract

BACKGROUND: Corticotroph tumor progression (CTP) leading to Nelson's syndrome (NS) is a severe and difficult-to-treat complication subsequent to bilateral adrenalectomy (BADX) for Cushing's disease. Its characteristics are not well described, and consensus recommendations for diagnosis and treatment are missing.
METHODS: A systematic literature search was performed focusing on clinical studies and case series (≥5 patients). Definition, cumulative incidence, treatment and long-term outcomes of CTP/NS after BADX were analyzed using descriptive statistics. The results were presented and discussed at an interdisciplinary consensus workshop attended by international pituitary experts in Munich on October 28, 2018.
RESULTS: Data covered definition and cumulative incidence (34 studies, 1275 patients), surgical outcome (12 studies, 187 patients), outcome of radiation therapy (21 studies, 273 patients), and medical therapy (15 studies, 72 patients).
CONCLUSIONS: We endorse the definition of CTP-BADX/NS as radiological progression or new detection of a pituitary tumor on thin-section MRI. We recommend surveillance by MRI after 3 months and every 12 months for the first 3 years after BADX. Subsequently, we suggest clinical evaluation every 12 months and MRI at increasing intervals every 2-4 years (depending on ACTH and clinical parameters). We recommend pituitary surgery as first-line therapy in patients with CTP-BADX/NS. Surgery should be performed before extrasellar expansion of the tumor to obtain complete and long-term remission. Conventional radiotherapy or stereotactic radiosurgery should be utilized as second-line treatment for remnant tumor tissue showing extrasellar extension.

Entities:  

Mesh:

Year:  2021        PMID: 33444221      PMCID: PMC8060870          DOI: 10.1530/EJE-20-1088

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  107 in total

1.  Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome.

Authors:  François R Jornayvaz; Guillaume Assie; Marie Bienvenu-Perrard; Joël Coste; Laurence Guignat; Jérôme Bertherat; Stéphane Silvera; Xavier Bertagna; Paul Legmann
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.

Authors:  Claudio De Tommasi; Mary Lee Vance; David O Okonkwo; Alfa Diallo; Edward R Laws
Journal:  J Neurosurg       Date:  2005-11       Impact factor: 5.115

3.  Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study.

Authors:  Krystallenia I Alexandraki; Gregory A Kaltsas; Andrea M Isidori; Helen L Storr; Farhad Afshar; Ian Sabin; Scott A Akker; Shern L Chew; William M Drake; John P Monson; G Michael Besser; Ashley B Grossman
Journal:  Eur J Endocrinol       Date:  2013-03-20       Impact factor: 6.664

4.  A Long-Term Study of the Treatment of Nelson's Syndrome With Gamma Knife Radiosurgery.

Authors:  James P Caruso; Mohana Rao Patibandla; Zhiyuan Xu; Mary Lee Vance; Jason P Sheehan
Journal:  Neurosurgery       Date:  2018-09-01       Impact factor: 4.654

5.  The effects of octreotide in a patient with Nelson's syndrome.

Authors:  F Kelestimur; C Utas; O Ozbakir; A Selçuklu; O Kandemir; N Ozcan
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

6.  Surgical management of Cushing's syndrome.

Authors:  T Imai; T Kikumori; H Funahashi; A Nakao
Journal:  Biomed Pharmacother       Date:  2000-06       Impact factor: 6.529

7.  Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up.

Authors:  T A Howlett; P N Plowman; J A Wass; L H Rees; A E Jones; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1989-09       Impact factor: 3.478

8.  A study of patients with Nelson's syndrome.

Authors:  M A Pereira; A Halpern; L R Salgado; B B Mendonça; M Nery; B Liberman; D H Streeten; B L Wajchenberg
Journal:  Clin Endocrinol (Oxf)       Date:  1998-10       Impact factor: 3.478

9.  Incidence of pituitary tumors following adrenalectomy. A long-term follow-up study of patients treated for Cushing's disease.

Authors:  K L Cohen; R H Noth; T Pechinski
Journal:  Arch Intern Med       Date:  1978-04

10.  Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.

Authors:  Elise Rousseau; Michael Joubert; Géraldine Trzepla; Jean Jacques Parienti; Thomas Freret; Marie Christine Vanthygem; Rachel Desailloud; Hervé Lefebvre; Antoine Coquerel; Yves Reznik
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

View more
  9 in total

Review 1.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

2.  Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency.

Authors:  F Ceccato; M Torchio; I Tizianel; M Peleg Falb; M Barbot; C Sabbadin; C Betterle; C Scaroni
Journal:  J Endocrinol Invest       Date:  2022-08-10       Impact factor: 5.467

Review 3.  Cushing's disease: role of bilateral adrenalectomy.

Authors:  Jérôme Bertherat
Journal:  Pituitary       Date:  2022-07-26       Impact factor: 3.599

Review 4.  Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.

Authors:  Xin He; James W Findling; Richard J Auchus
Journal:  Pituitary       Date:  2022-04-26       Impact factor: 3.599

Review 5.  The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.

Authors:  Daniela Regazzo; Alessandro Mondin; Carla Scaroni; Gianluca Occhi; Mattia Barbot
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

6.  TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome.

Authors:  Luis Gustavo Perez-Rivas; Julia Simon; Adriana Albani; Sicheng Tang; Sigrun Roeber; Guillaume Assié; Timo Deutschbein; Martin Fassnacht; Monica R Gadelha; Ad R Hermus; Günter K Stalla; Maria A Tichomirowa; Roman Rotermund; Jörg Flitsch; Michael Buchfelder; Isabella Nasi-Kordhishti; Jürgen Honegger; Jun Thorsteinsdottir; Wolfgang Saeger; Jochen Herms; Martin Reincke; Marily Theodoropoulou
Journal:  Acta Neuropathol Commun       Date:  2022-09-19       Impact factor: 7.578

Review 7.  Aggressive corticotroph tumors and carcinomas.

Authors:  Hélène Lasolle; Alexandre Vasiljevic; Emmanuel Jouanneau; Mirela Diana Ilie; Gérald Raverot
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

8.  Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.

Authors:  Pia Burman; Jacqueline Trouillas; Marco Losa; Ann McCormack; Stephan Petersenn; Vera Popovic; Marily Theodoropoulou; Gerald Raverot; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-09-19       Impact factor: 6.558

9.  Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis.

Authors:  Eleni Papakokkinou; Marta Piasecka; Hanne Krage Carlsen; Dimitrios Chantzichristos; Daniel S Olsson; Per Dahlqvist; Maria Petersson; Katarina Berinder; Sophie Bensing; Charlotte Höybye; Britt Edén Engström; Pia Burman; Cecilia Follin; David Petranek; Eva Marie Erfurth; Jeanette Wahlberg; Bertil Ekman; Anna-Karin Åkerman; Erik Schwarcz; Gudmundur Johannsson; Henrik Falhammar; Oskar Ragnarsson
Journal:  Pituitary       Date:  2021-05-25       Impact factor: 4.107

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.